Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma

Medical Oncology

Volumn 15, Issue SUPPL. 1, 1998, Pages

  San Miguel, Jesús F ^a   García Sanz, Ramón ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Anaemia; Erythropoietin; Lymphoma; Multiple myeloma

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL RESEARCH; DOSE RESPONSE; DRUG RESPONSE; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANEMIA; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA;

EID: 0031659314     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. San Miguel JF. Supportive therapy for complications in multiple myeloma. In: Education sessions of the second meeting of the European Haematology Association, 1996. Blackwell Science Oxford: Oxford, 1996, pp 12-16.
2. San Miguel JF et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-455.
3. Faquin WC, Scheneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987.
4. Jelkman W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and isolated perfused rat kidneys. Life Sci 1992; 50: 301.
5. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992; 80: 1639.
6. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648-653.
7. Doll DC, Weiss RB. Neoplasia and the erythron. J Clin Oncol 1993; 3: 429.
8. Skilling JR, Sridhar FG, Wong C et al. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 1993; 16: 22-25.
9. Singh A et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91: 251.
10. Cazzola M et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995; 86: 4446-4453.
11. Österborg A et al for the European Study Group of Erythropoietin (epoietin beta). Treatment in multiple myeloma and non-Hodgkin's lymphoma. Recombinant human erythropoietin in transfusion-dependent patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study. Blood 1996; 87: 2675-2682.
12. Spivak JL. The application of recombinant-erythropoietin in anemic patients with cancer. Sem Oncol 1992; 19: 25-28.
13. Cazzola M et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79: 29-37.
14. Rose E, Rai K, Revicki D, Brown, R, Reblando J and the EPO anemia of CLL study group. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoietin alfa (EPO). Blood 1994; 86 (suppl 1): 2091a.
15. Rodriguez MA et al. Results of the salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-1741.
16. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993; 29A (suppl 2): S2-S8.
17. Wood PA, Hrushesky WJ. Cisplatin associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650.
18. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 1991; 68: 1101.
19. Mohandas K, Aledort L. Transfusion requirements, risks and costs for patients with malignancy. Transfusion 1995; 35: 427.
20. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89: 4248-4267.
21. Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and survival factor. Blood 1991; 77: 1228.
22. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990; 248: 378.
23. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993; 11: 88-94.
24. Ludwig H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699.
25. Garton JP et al. Epoietin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled double blind trial. Arch Int med 1995; 155: 2069-2074.
26. Oster W et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8: 956-962.
27. Platanias LC et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021-2026.
28. Vannucchi AM et al. Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO compatible, HLA-identical, allogeneic bone marrow transplant patients. Leukemia 1992; 6: 215.
29. Ayash L et al. Recombinant human erythropoietin (EPO) in anemia associated with autologous bone marrow transplantation (ABMT). Blood 1990; 76: 131a.
30. Mitus AJ, Antin JH, Rutheford CJ, McGarigle C, Goldberg MA. Recombinant human erythropoietin (rHuEPO) in allogeneic bone marrow transplantation (BMT). Blood 1992; 78: 275a.
31. Pene R et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous bone marrow transplantation. Bone Marrow Transplant 1993; 11: 219.
32. Chao NJ et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823-2828.
33. Lazzarus HM et al. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: Implications for erythropoietin therapy in this setting. Bone Marrow Transplant 1992; 10: 71-75.
34. Storb R et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graf-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729.
35. Vannucchi AM et al. Impaired erythropoietin production in mice treated with cyclosporin-A. Blood 1991; 78: 1615.
36. Schrezenmeier H et al. Serum erythropoietin and serum transferrin receptor levels in aplastic anemia. Br J Haematol 1994; 88: 286.
37. Pettegel R et al. Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. Bone Marrow Transplant 1994; 14: 125-130.
38. + progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, interferon-γ and erythropoietin. Blood 1993; 81: 2579-2584.
39. Ludwig H et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063.